Growth Potential Mid-sized pharmaceutical manufacturer with a lean team (11-50 employees) and annual revenue in the low millions presents an opportunity for scalable outsourced services, such as clinical data management, pharmacovigilance, regulatory affairs support, or specialized CRO partnerships to accelerate project timelines.

Compliance Focus Active in an industry with stringent safety and regulatory requirements, suggesting a need for sponsor-level pharmacovigilance, drug safety analytics, adverse event processing, and regulatory submissions outsourcing to ensure compliance while controlling internal headcount.

Tech Modernization Current tech stack includes WordPress, Microsoft 365, and PHP with common web technologies; position for modernization services, cloud-based collaboration, data security enhancements, and digital transformation to enable safer, faster drug safety workflows.

Geographic Target Based in Austin, TX, indicating potential alignment with regional pharma clusters and local partnerships; explore services that support US-based clinical safety operations, post-market surveillance, and incident reporting adhering to FDA and other regulatory standards.

Competitive Benchmarking Revenue scale and headcount place Drug Safety Institute between small CROs and mid-sized firms; target capabilities that complement larger competitors (e.g., specialized safety data analytics, rapid safety signal detection, and cost-effective outsourcing) to win as a preferred partner for mid-market projects.